Pamabrom

Pamabrom is a diuretic that acts on the opioid receptor-nitric oxide (NO) -cyclic guanosine monophosphate (cGMP) -K+ channel pathway. Pamabrom exerts peripheral antinociceptive activity by activating this pathway. The mechanism involves activating opioid receptors, promoting the release of nitric oxide, and then influencing cyclic guanosine monophosphate and K channels to produce an analgesic effect. Pamabrom is orally active and is mainly used in the research and treatment of premenstrual syndrome and primary dysmenorrhea[1].

Product Specifications

CAS Number

[606-04-2]

UNSPSC

12352005

Hazard Statement

H302

Target

Adenosine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/pamabrom.html

Purity

99.92

Solubility

DMSO : 150 mg/mL (ultrasonic)

Smiles

O=C(N1C)N(C)C2=C(N=C(Br)N2)C1=O.CC(C)(N)CO

Molecular Formula

C11H18BrN5O3

Molecular Weight

348.20

Precautions

H302

References & Citations

[1]Ortiz MI, et al. Effect of nitric oxide-cyclic GMP-K+ channel pathway blockers, naloxone and metformin, on the antinociception induced by the diuretic pamabrom. Can J Physiol Pharmacol. 2023 Jan 1;101 (1) :41-51.